CytRx’s INNO-206 Inhibits Pancreatic Cancer Growth In Animal Trials

CytRx has announced that treatment with its cancer drug candidate INNO-206 resulted in a statistically significant reduction in the average primary tumor size in an animal model of pancreatic cancer.

Reportedly, treatment with CytRx’s INNO-206 resulted in a statistically significant (p<0.005) three-fold reduction in the average primary tumor size, compared to the control. Treatment with doxorubicin showed only a 30% primary tumor reduction, which was not statistically significant, said the company.

In a parallel experiment, treatment with gemcitabine (the approved and most commonly prescribed drug for pancreatic cancer) resulted in activity comparable to doxorubicin, with an approximate 30% primary tumor volume reduction.

Steven Kriegsman, president and CEO of CytRx, said: “Few drugs show any benefit for patients suffering from this rapidly progressing and deadliest of cancers, and I am personally delighted that INNO-206 effectively treated tumors in these experimental animals.

“We now have further evidence that the putative targeting mechanism of INNO-206 could have significant therapeutic benefit in multiple types of cancer,” he added.